Back to the Future: Psychopharmacology
Come back to the future with your colleagues at our Spring Meeting, where everything old is new again!
|
Educational Objectives At the end of the educational activity, the learner will be able to:
Who should attend? This educational activity is intended for psychiatrists, primary care physicians, emergency physicians, psychologists, social workers, physician assistants, registered nurses, advance practice nurses, compliance officers and clinic administrators. All mental health professionals and general health professionals are welcome, including students and residents. |
Overview
The history of medication reaches back to when our ancestors first ingested plants with intent to treat ailments. As William Osler put it, “The desire to take medicine is perhaps the greatest feature which distinguishes man from animals.” The development of pharmaceuticals owes as much to serendipity as science. Fleming’s 1928 discovery of penicillin from mold is by far the most famous example of such luck (followed up by intellectual pursuit, of course.) The first antipsychotic, chlorpromazine, started its life in anesthesia. And our old and perpetual friend, Lithium, began its career in gout. At the MPS Spring Program, we will delve deeply into pharmacology, focusing on medications, old and new. Attendees will learn cutting edge management of our oldest and most effective drugs: clozapine and lithium. We will examine our newest (and first) non-dopaminergic antipsychotic. We will learn new skills to help our patients with one of mankind’s oldest afflictions: addiction. Other exciting topics include treatment of depression and ADHD, and updates on ketamine and psilocybin. Spend the day with MPS to hone your skills with our remarkable psychiatric pharmaceutical toolbox. Come back to the future with your colleagues at our Spring Meeting, where everything old is new again! And, to end with another gem from Osler: “Use all new medications while they still work.” Exhibitors
Axsome - Bristol Meyer Squibb - Intra-Cellular Therapies, Inc. - Teva Medical |
Accreditation and Designation Statement
In support of improving patient care, this activity has been planned and implemented by American Psychiatric Association (APA) and Minnesota Psychiatric Society (MPS). The American Psychiatric Association (APA) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
The American Psychiatric Association (APA) designates this live activity for a maximum of 7.25 AMA PRA Category 1 Credit™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Jointly provided by the American Psychiatric Association and the Minnesota Psychiatric Society